IMMX

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Wall Street analysts forecast IMMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Immix Biopharma Inc revenue for the last quarter amounts to -7.66M USD, increased 3.62 % YoY.

Immix Biopharma Inc. EPS for the last quarter amounts to -6278232.00 USD, increased 45.75 % YoY.

Immix Biopharma Inc (IMMX) has 18 emplpoyees as of December 15 2025.

Today IMMX has the market capitalization of 368.72M USD.